期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他莫昔芬对人肝癌细胞增殖及ER表达影响的研究 被引量：1

Effects of tamoxifen on proliferation and ER expression of human hepatocellular carcinoma cells
暂未订购
导出
摘要 目的:研究他莫昔芬(Tamoxifen,TAM)对人肝癌HepG2细胞增殖和HepG2细胞ER表达的影响。方法:按照TAM的浓度不同分为7.5μmol/L、15μmol/L、30μmol/L3组,对照组不加TAM,每孔加入1×105mL-1细胞0.1mL,培养24、48和72h,采用MTT法测定抑制率;细胞免疫组化染色观察TAM对肝癌细胞ER的表达的影响。结果:TAM抑制人肝癌细胞增殖及ER表达,并具有时间-浓度依赖。结论:TAM可能通过影响肝癌细胞ER的表达抑制肝癌细胞增殖。 Objective：To study the effects of tamoxifen on proliferation and ER expression of human hepatocellular carcinoma cells.Methods：HepG2 cells were treated with tamoxifen at different concentration and different action time.MTT was used to determine the suppression rate of human hepatocellular carcinoma cell.The effects of tamoxifen on human hepatocellular carcinoma cell ER performance were observed by immunohistochemistry.Results：Tamoxifen inhibited the proliferation of human hepatocellular carcinoma cells and suppressed human hepatocellular carcinoma cell ER performence.Conclusions：Tamoxifen may suppress human hepatocellular carcinoma cell proliferation ER performance.
作者 白文坤 王文奇 时昌文 吴洪文
机构地区 山东大学附属千佛山医院超声诊疗科 山东大学附属千佛山医院消化内科 山东大学附属千佛山医院普外中心实验室 山东省淄博市第一人民医院消化科
出处 《中国现代普通外科进展》 CAS 2008年第5期386-388,共3页 Chinese Journal of Current Advances in General Surgery
基金 山东省自然科学基金资助项目(Y2002CO1)
关键词 肝肿瘤 细胞增殖 他莫昔芬 受体 雌激素 Hepatocellular·Proliferation·Tamoxifen·Receptor,estrogen
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Lu YS, Hsu C, Li CC, et al. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma [J]. Hepatogastroenterology, 2004,51 (57):815-819.
  • 2Castro-Rivera E, Safe S. 17 beta-estradiol and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER- subtype, cell and promoter context [J]. Stewid Biochem Mol Biol, 2003,84( 1 ): 23-31.
  • 3Waalkes MP, Liu J, Chen H, et al. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero[J]. J Natl Cancer Inst, 2004,96 (6):466-474.
  • 4Marino M, Distefano E, Caporali S, et al. beta-estradiol stimulation of DNAsynthesisrequires different PKC isoforms in HepG2 and MCF7 cells[d].J Cell Physiol, 2001,188(2):170-177.
  • 5Zhang CC, Shapiro DJ. Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor- induced apoptosis [J]. J Bid Chem, 2000,275 ( 1 ):479-486.
  • 6Liang Y, Hou M, Kallab AM. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbetal [J].Int J Oncol, 2003,23 (2):369-380.
  • 7Riss TL, Moravec RA. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin,and plating density in cell-based eytotoxieity assays [J]. Assay Drug Dev Technol, 2004,2 ( 1 ) :51-62.
  • 8Brandt S, Heller H, Schuster KD, et al. Tamoxifen induces suppression of cell viability and apoptosis in the human hepatobl astoma cell line HepG2 via down-regulation of telomerase activity [J].Liver Int, 2004,24( 1 ):46-54.
  • 9Brandt S, Heller H, Schuster KD, et al. The tamoxifen-induced suppression of telomerase activity in the human hepatoblastoma cell line HepG2: a result of post-translational regulation [J]. J Cancer Res Clin Oncol, 2005,131(2):120-128.
  • 10Herold C, Ganslmayer M, Ocker M, et al. Combined in vitro antitumoral action of tamoxifen and retinoic acid derivatives in hepatoma cells[J]. IntJ Oncol, 2002,20(1):89-96.

同被引文献15

  • 1季加孚.我国胃癌防治研究三十年回顾[J].中国肿瘤临床,2013,40(22):1345-1351.
  • 2Zhang C, Gao GR. l.v , et al. Protease-activated recep- tor-2 induces expression of vascular endothelial growth factr and cyclooxygenase-2 via the mitogen-activated pro rein kinase pathway in gastric cancer cells[J]. Oncol Rep. 2012,28(5) :1917-1923.
  • 3Kim MJ,Cho SI,Lee KO, eI al. Effects of 17-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines [J]. J Gastric Cancer, 201.'I, 13 (3).. 172 178.
  • 4Kretzer NM, Cherian MT, Mao CJ, et al. A noncompeti- tive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor alpha[J]. J Biol Chem, 2010,285 (53) : 41863-41873.
  • 5Chen S, Liu H, Li J, et al. Risk of gastric and colorectal cancer after tamoxifen use for breast cancer: a systematic review and eta-analysis[J]. J Clin Gastroenterol, 2014, [Epub ahead of print].
  • 6Xie X,Wu MY, Shou LM, et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pan- creatic cancer cell lines through inhibition of the protein kinase C signaling pathway[J]. Oncol Lett, 2015,9 (2) : 837-844.
  • 7Chandanosa E, Lindblada M,Rubiob CA, et al. Tamoxifen exposure in relation to gastric adenocarcinoma develop- ment[J]. Eur J Cancer,2008,44(7) ..1007-1014.
  • 8Salami S,Karami-Tehrani F. Biochemical studies of apop- tosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines [J]. Clin Biochem,2003,36(4)247-253.
  • 9Jiang X,Patterson NM, Ling Y, et al. Low concentrations of the soy phytoestrogen genistein induce proteinase in- hibitor 9 and block killing of breast cancer cells by im- mune eells[J]. Endocrinology, 2008,149 (11 ) : 5366-5373.
  • 10Zembutsu H. Pharmacogenomies toward personalized tamox- ifen therapy for breast cancer[J]. Pharmacogenomics, 2015, 16(3) ..287-296.

引证文献1

二级引证文献2

中国现代普通外科进展
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部